Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.
Gordon Cummins
Advertisement
Articles by Gordon Cummins
Advertisement
Latest Updated Articles
Refining, Rethinking, and Decentralizing Clinical ResearchFebruary 26th 2021
Advertisement
Advertisement
Trending on PharmExec
1
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
2
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
3
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
4
Developing New Therapies Across Multiple Regulatory Landscapes
5